Latest Depression News

Page 11 of 14
Prospect Resources has released compelling metallurgical test results from its Mumbezhi Copper Project in Zambia, demonstrating robust, high-grade copper concentrates and strong recoveries that support plans for a central processing hub.
Maxwell Dee
Maxwell Dee
17 July 2025
Bowen Coking Coal Limited has had its ASX trading suspension lifted following its disclosure on funding efforts amid challenging market conditions. The company confirmed compliance with ASX rules, paving the way for immediate reinstatement.
Maxwell Dee
Maxwell Dee
14 July 2025
Bowen Coking Coal Limited (BCB) has responded to ASX inquiries about its liquidity challenges, working capital needs from transitioning to an owner-operator model, and deteriorating operating margins, affirming compliance and financial viability despite market pressures.
Maxwell Dee
Maxwell Dee
14 July 2025
Bowen Coking Coal has started owner-operated mining at its Burton Mine Complex with a reduced fleet and production focus, responding to weak global steel markets and low coal prices. The company is actively pursuing refinancing and strategic funding to sustain operations during this challenging period.
Maxwell Dee
Maxwell Dee
14 July 2025
Clean Seas Seafood shareholders have voted to approve Yumbah Aquaculture’s acquisition scheme, setting the stage for delisting and a significant ownership change. The deal offers shareholders a cash option or a scrip alternative, with expert backing and board endorsement.
Victor Sage
Victor Sage
8 July 2025
Legacy Minerals has acquired exploration rights to the Nico Young nickel-cobalt deposit in NSW, boasting one of Australia’s largest contained resources with significant strategic potential amid current market lows.
Maxwell Dee
Maxwell Dee
1 July 2025
Bowen Coking Coal has announced it will remain suspended on the ASX as it reassesses its operational plans and explores financing options amid challenging market conditions.
Maxwell Dee
Maxwell Dee
26 June 2025
Tryptamine Therapeutics has secured ethics approval to begin a pioneering clinical trial of TRP-8803, an IV-infused psilocin treatment, targeting adult patients with Binge Eating Disorder. The trial aims to evaluate safety and efficacy, with initial results expected by the end of 2025.
Ada Torres
Ada Torres
23 June 2025
Richmond Vanadium Technology slows key project activities and reshapes its leadership team to navigate a prolonged period of low vanadium prices while advancing battery technology development.
Maxwell Dee
Maxwell Dee
23 June 2025
Bowen Coking Coal has surpassed its full-year 2025 production and sales targets ahead of schedule while transitioning the Burton Mine Complex to an owner-operator model. However, ongoing market challenges and funding uncertainties cast a shadow over its near-term outlook.
Maxwell Dee
Maxwell Dee
20 June 2025
Emyria has landed a multi-year funding deal with Medibank to support its Empax PTSD program at Perth Clinic, marking a first for private insurer-backed psychotherapy in Australia. The company also announces a $4 million capital raise to fuel national expansion.
Ada Torres
Ada Torres
18 June 2025
Bioxyne Limited has raised its FY2025 revenue guidance to $28 million, driven by explosive growth in Australian pharmaceutical manufacturing and the upcoming commercial production of MDMA capsules. The company is also making strides in expanding its footprint across Europe.
Victor Sage
Victor Sage
12 June 2025

Browse the archive

Full archive